Economics of TruCAD
• Total addressable market is approximately 10 million U.S. adults presenting with symptoms of CAD.
• Potential expansion into “at risk” adult health testing market is 8-10 times greater.
• The market will expand by multiples with worldwide use, especially in countries with limited access to sophisticated cardiac imaging systems.
• Unlike existing invasive or non-invasive cardiac imaging systems, TruCAD could be employed multiple times over the course of a patient's treatment to monitor the disease process, and tailor various therapies.